Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2008-000305-11 | Other Identifier | Ethical Comitee, Copenhagen, Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GLP-1 | Experimental | time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g). |
|
| NaCl | Placebo Comparator | time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g). |
|
| GIP | Experimental | time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| glucagon like peptide -1 | Other | continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes |
| |
| Measure | Description | Time Frame |
|---|---|---|
| phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose | 2 hours |
| Measure | Description | Time Frame |
|---|---|---|
| maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine) | 2 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Urd Kielgast, MD | unafilliated | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dept. of Endocrinology, Hvidovre Hospital | Copenhagen | 2650 | Denmark |
Not provided
| ID | Term |
|---|---|
| D052216 | Glucagon-Like Peptide 1 |
| D054795 | Incretins |
| ID | Term |
|---|---|
| D004763 | Glucagon-Like Peptides |
| D052336 | Proglucagon |
| D005768 | Gastrointestinal Hormones |
| D006728 | Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| NaCl |
| Other |
infusion with NaCl for 120 minutes as placebo-arm |
|
| glucose dependent insulinotropic polypeptide | Other | continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes. |
|
| D006730 |
| Hormones, Hormone Substitutes, and Hormone Antagonists |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |